VIR

Based on Vir Biotechnology, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Vir Biotechnology do?

Vir Biotechnology is a commercial-stage immunology company that develops treatments and preventions for serious infectious diseases. Its programs span COVID-19, hepatitis B, influenza A, and HIV, using monoclonal antibodies and other immunological approaches. The company works with a network of global partners and grant-funding organizations to advance its pipeline.

Does VIR pay dividends?

Vir Biotechnology does not pay a dividend. As a commercial-stage biotech, the company directs its resources toward research, clinical development, and partnership activities. Investors should not expect income distributions from VIR in the near term.

When does VIR report earnings?

Vir Biotechnology follows a standard quarterly earnings cadence for US-listed companies. For the exact timing of upcoming results, check the investor relations section of Vir's official website, as specific dates are subject to change.

Is VIR a good stock to buy?

UQS Score rates VIR as Poor overall, reflecting Weak Quality and Moat pillars alongside an Elevated Valuation. The Good Risk rating is a relative positive. Whether VIR fits a portfolio depends on an investor's risk tolerance and view on the company's pipeline prospects. The full pillar breakdown is available to UQS Pro members.

Is VIR overvalued?

UQS Score's Valuation pillar for VIR is rated Elevated, suggesting the current market price may not offer a wide margin of safety relative to the company's financial fundamentals. This does not constitute a sell signal, but it is a factor investors should weigh alongside pipeline progress.

How does VIR compare to its competitors?

Compared to peers like Nektar Therapeutics, Harmony Biosciences, and Recursion Pharmaceuticals, Vir is distinguished by its exclusive focus on infectious disease immunology and its reliance on monoclonal antibody technology. Each competitor pursues a different therapeutic focus or technology platform. UQS Pro members can view side-by-side quality scores.

What is VIR's market cap bracket?

Vir Biotechnology is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk than large- or mega-cap peers, though it may also offer greater upside potential if clinical programs succeed.

Who founded Vir Biotechnology?

Vir Biotechnology was incorporated in 2016. Founding context and leadership history are publicly available through the company's official filings and investor relations materials for those seeking detailed background on the organization's origins.

Is VIR a long-term quality investment?

As a long-term quality indicator, UQS Score rates VIR as Poor, driven by Weak Quality and Moat scores. Long-term quality investing typically favors companies with durable competitive advantages and strong fundamentals — areas where Vir currently scores below sector peers. The Good Risk rating offers some reassurance on near-term stability.

What is the main competitive advantage of Vir Biotechnology?

Vir's approach centers on leveraging human immune system insights — particularly around memory B cells and broadly neutralizing antibodies — to develop therapies for diseases that have resisted conventional treatments. Its partnerships with organizations like GlaxoSmithKline and Gilead Sciences provide development and commercialization support. However, UQS Score rates its Moat as Weak, indicating these advantages are not yet deeply entrenched.

What sector does VIR belong to?

Vir Biotechnology operates in the Healthcare sector, specifically within the biotechnology and immunology subsegment. It focuses on infectious disease — a niche that has seen significant attention following the COVID-19 pandemic but remains highly competitive and dependent on clinical outcomes.

Is VIR a growth stock or value stock?

Based on UQS pillar labels, VIR carries a Neutral Growth rating and an Elevated Valuation — a combination that makes it difficult to classify cleanly as either a growth or value play. It lacks the discounted valuation of a traditional value stock and has not yet demonstrated the consistent revenue expansion typical of high-conviction growth names.

Vir Biotechnology, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

Vir Biotechnology, Inc. shows steady but unspectacular growth, typical for mature companies.

Vir Biotechnology, Inc. maintains a reasonable risk profile with manageable debt levels.

Vir Biotechnology, Inc. appears expensively valued relative to its fundamentals and growth prospects.

Vir Biotechnology, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for VIR.

The UQS (Unified Quality Score) for Vir Biotechnology, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Vir Biotechnology, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Vir Biotechnology, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.